Receptors, Antigen, T-Cell
"Receptors, Antigen, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
Descriptor ID |
D011948
|
MeSH Number(s) |
D12.776.543.750.705.816.824
|
Concept/Terms |
Receptors, Antigen, T-Cell- Receptors, Antigen, T-Cell
- T-Cell Antigen Receptor
- Antigen Receptor, T-Cell
- Receptor, T-Cell Antigen
- T Cell Antigen Receptor
- T-Cell Receptors
- Receptors, T-Cell
- T Cell Receptors
- T-Cell Receptor
- Receptor, T-Cell
- T Cell Receptor
- Receptors, T-Cell Antigen
- Receptors, T Cell Antigen
- T-Cell Antigen Receptors
- Antigen Receptors, T-Cell
- Antigen Receptors, T Cell
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Antigen, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Antigen, T-Cell".
- Receptors, Antigen, T-Cell
- Complementarity Determining Regions
- Receptor-CD3 Complex, Antigen, T-Cell
- Receptors, Antigen, T-Cell, alpha-beta
- Receptors, Antigen, T-Cell, gamma-delta
This graph shows the total number of publications written about "Receptors, Antigen, T-Cell" by people in this website by year, and whether "Receptors, Antigen, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 2 | 1 | 3 |
1996 | 2 | 3 | 5 |
1997 | 5 | 0 | 5 |
1998 | 4 | 4 | 8 |
1999 | 4 | 3 | 7 |
2000 | 0 | 5 | 5 |
2001 | 7 | 2 | 9 |
2002 | 3 | 3 | 6 |
2003 | 4 | 7 | 11 |
2004 | 5 | 7 | 12 |
2005 | 6 | 6 | 12 |
2006 | 5 | 4 | 9 |
2007 | 1 | 5 | 6 |
2008 | 3 | 3 | 6 |
2009 | 3 | 2 | 5 |
2010 | 4 | 2 | 6 |
2011 | 1 | 4 | 5 |
2012 | 7 | 2 | 9 |
2013 | 6 | 4 | 10 |
2014 | 7 | 3 | 10 |
2015 | 5 | 3 | 8 |
2016 | 7 | 8 | 15 |
2017 | 3 | 2 | 5 |
2018 | 10 | 5 | 15 |
2019 | 7 | 7 | 14 |
2020 | 5 | 3 | 8 |
2021 | 7 | 4 | 11 |
2022 | 1 | 14 | 15 |
2023 | 0 | 9 | 9 |
2024 | 3 | 11 | 14 |
2025 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Antigen, T-Cell" by people in Profiles.
-
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025 Jun 10; 9(11):2763-2772.
-
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun 05; 145(23):2762-2767.
-
Identification of shared neoantigens derived from frameshift mutations in the APC gene. Front Immunol. 2025; 16:1574955.
-
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
-
Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function. Nat Cell Biol. 2025 May; 27(5):835-846.
-
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer. 2025 Feb 09; 13(2).
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy. Sci Immunol. 2024 Sep 13; 9(99):eadp6529.
-
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood Adv. 2024 08 13; 8(15):4164-4168.